Arvinas presents preclinical data on BCL6 degrader ARV-393 in lymphoma

Bitget2026/11/03 12:24

By:Bitget

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Arvinas’ VEPPANU (vepdegestrant) received FDA approval on May 1, 2026, becoming the first approved PROTAC protein degrader.
Rigel licensed VEPPANU in May 2026; commercial availability began in August 2026, with potential milestone payments and tiered royalties.
Cash runway extends into the second half of 2028; clinical-stage partnerships with Pfizer and Novartis generated more than $800 million.
Novartis is evaluating luxdegalutamide in three Phase 2 combination trials under a licensing deal potentially worth more than $1 billion.
ARV-393’s Phase 1 trial is enrolling lymphoma patients for monotherapy treatment or combination treatment with glofitamab.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Arvinas presents preclinical data on BCL6 degrader ARV-393 in lymphoma

You may also like

Crypto prices